secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001398733-25-000027
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive Q3 net loss $15.4M; Anaphylm PDUFA Jan 31, 2026, launch prep ongoing
------------------------------------------------------------------------------

- Total revenue $12.8M (+4% YoY excluding one-time 2024 deferred revenue); net loss $15.4M ($0.14/sh) vs $11.5M loss in Q3 2024.
- Cash $129.1M; full-year 2025 revenue guidance $44-50M, non-GAAP adjusted EBITDA loss $47-51M.
- Anaphylm NDA on track for Jan 31, 2026 PDUFA; FDA will not hold AdCom; US launch planned Q1 2026 if approved.
- Two new Anaphylm patents issued Oct 2025 extending protection to 2037; IND for AQST-108 topical epinephrine gel for alopecia areata on track for Q4 2025.
- Added clinical leadership for AdrenaVerse pipeline; supply chain largely unaffected by tariffs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000139873325000027/0001398733-25-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000139873325000027/aqst-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001398733-25-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer